Clinical trials: Patients with Advanced Solid Tumors
Advanced HCC, Other Solid Tumors
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with Tislelizumab ± Bevacizumab in patients with Advanced HCC and Other Solid Tumors.
- Trial name
- NCT05906524
- Testing
- KD6001, Tislelizumab, Bevacizumab
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
Non Small Cell Lung Cancer, Solid Tumor
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic…
- Trial name
- NCT07232420
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor Malignancies
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
This is a Phase I, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, PK/pharmacodynamic (PD) characteristics, and anti-tumor activity of JSKN016HC in subjects with advanced malignant solid tumors.
- Trial name
- NCT07475559
- Testing
- JSKN016HC
- Where
- Australia
- Volunteers
- 42 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Clear-Cell Renal Cell Carcinoma
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment…
- Trial name
- NCT04518046
- Testing
- Sitravatinib, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mirati Therapeutics Inc.
Neoplasms
A Study Of PF-03732010 In Patients With Advanced Solid Tumors
P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be.
- Trial name
- NCT00557505
- Testing
- PF-03732010
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 43 people
- Sponsor
- Pfizer
Advanced Cancer, Metastatic Cancer
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumors
- Trial name
- STMN1-LP (NCT01505153)
- Testing
- pbi-shRNA STMN1 LP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gradalis, Inc.
Advanced Solid Tumor
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid…
- Trial name
- NCT06422520
- Testing
- BGB-C354, Tislelizumab
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 63 people
- Sponsor
- BeOne Medicines
Colorectal Cancer, Lung Cancer
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer
- Trial name
- NCT00054977
- Testing
- GM-CT-01, 5-fluorouracil
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Galectin Therapeutics Inc.
Solid Tumors
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
This study is open to Japanese adults with different types of advanced cancer (solid tumors). People can join the study if their cancer has spread, and previous treatments were not successful or no treatments exist.
- Trial name
- NCT07176975
- Testing
- BI 1831169, nivolumab
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.
- Trial name
- NCT01363024
- Testing
- MFGR1877S
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Carcinoma
ARQ 501 in Combination With Docetaxel in Patients With Cancer
The purpose of this study is to determine the safety of ARQ 501 in combination with docetaxel in patients with advanced or metastatic cancer.
- Trial name
- NCT00099190
- Testing
- ARQ 501
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Solid Tumor, Unspecified, Adult
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2).
- Trial name
- NCT04643418
- Testing
- MPB-1734
- Where
- Taiwan
- Volunteers
- 81 people
- Sponsor
- MegaPro Biomedical Co. Ltd.
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Neoplasms, Malignant
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after intravenous infusion of [14C]-AVE8062 to humans To determine the pharmacokinetics of AVE8062 and RPR258063 and their contribution…
- Trial name
- NCT01063946
- Testing
- Ombrabulin (AVE8062)
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- Sanofi
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types.
- Conditions
- Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT06034860
- Testing
- MT-8421, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Molecular Templates, Inc.
Advanced Solid Tumors
Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies
This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies. This study will be the first to administer TAK 701 to humans.
- Trial name
- NCT00831896
- Testing
- TAK-701
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumour
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
- Trial name
- NCT07111546
- Testing
- LBL-024 for Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection
- Where
- 16 sites in China
- Volunteers
- 140 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
The purpose of this study is to characterize the effect of repeat-dose administration of brigatinib 180 milligram (mg) once daily (QD) on the single-dose pharmacokinetics (PK) of midazolam.
- Trial name
- NCT03420742
- Testing
- Midazolam, Brigatinib
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 24 people
- Sponsor
- Takeda
Cancer, Solid Tumor
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
The purpose of this study is to determine the safety and tolerability of RXC004 as monotherapy and in combination with Nivolumab in patients with advanced malignancies.
- Trial name
- NCT03447470
- Testing
- RXC004, Nivolumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 46 people
- Sponsor
- Redx Pharma Ltd